Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-222904
Filing Date
2026-05-14
Accepted
2026-05-14 08:30:46
Documents
81
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20260331.htm   iXBRL 10-Q 2654709
2 EX-10.1 cadl-ex10_1.htm EX-10.1 49359
3 EX-31.1 cadl-ex31_1.htm EX-31.1 17027
4 EX-31.2 cadl-ex31_2.htm EX-31.2 17031
5 EX-32.1 cadl-ex32_1.htm EX-32.1 10059
6 EX-32.2 cadl-ex32_2.htm EX-32.2 10484
  Complete submission text file 0001193125-26-222904.txt   9842789

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20260331.xsd EX-101.SCH 1414546
85 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20260331_htm.xml XML 1486644
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 26975989
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)